Skip to main content
Journal cover image

Criterion validity of Medicare chemotherapy claims in Cancer and Leukemia Group B breast and lung cancer trial participants.

Publication ,  Journal Article
Lamont, EB; Herndon, JE; Weeks, JC; Henderson, IC; Lilenbaum, R; Schilsky, RL; Christakis, NA
Published in: J Natl Cancer Inst
July 20, 2005

To determine the accuracy with which Medicare claims data measure chemotherapy use in elderly Medicare beneficiaries with cancer, we performed a criterion validation study. We compared gold-standard clinical trial data for 175 elderly cancer patients treated in two Cancer and Leukemia Group B (CALGB) breast and lung cancer trials (i.e., 45 from trial 9344 and 130 from trial 9730) with contemporaneous ambulatory and in-patient Medicare health insurance claims data from Centers for Medicare and Medicaid Services (CMS). The breast trial participants studied were those elderly enrolled between 1995 and 1997 and treated with doxorubicin and cyclophosphamide or this combination with paclitaxel. The lung trial participants studied were those elderly enrolled between 1998 and 2000 and treated with paclitaxel and carboplatin or paclitaxel alone. Comparing CALGB data with Medicare claims, we found the crude sensitivity for chemotherapy administration was 93% (95% confidence interval [CI] = 88% to 96%). Individual chemotherapy agents had similarly high sensitivities, ranging from 81% (95% CI = 70% to 89%) for carboplatin to 91% (95% CI = 79% to 98%) for cyclophosphamide. Agent-specific specificities were 100%. CMS data reliably captured repeat administration of chemotherapy to within one cycle. Administrative Medicare claims data appear to be a valid source of information for chemotherapy administered to elderly Medicare beneficiaries with cancer.

Duke Scholars

Published In

J Natl Cancer Inst

DOI

EISSN

1460-2105

Publication Date

July 20, 2005

Volume

97

Issue

14

Start / End Page

1080 / 1083

Location

United States

Related Subject Headings

  • United States
  • Retrospective Studies
  • Reproducibility of Results
  • Randomized Controlled Trials as Topic
  • Paclitaxel
  • Oncology & Carcinogenesis
  • Multicenter Studies as Topic
  • Medicare
  • Male
  • Lung Neoplasms
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Lamont, E. B., Herndon, J. E., Weeks, J. C., Henderson, I. C., Lilenbaum, R., Schilsky, R. L., & Christakis, N. A. (2005). Criterion validity of Medicare chemotherapy claims in Cancer and Leukemia Group B breast and lung cancer trial participants. J Natl Cancer Inst, 97(14), 1080–1083. https://doi.org/10.1093/jnci/dji189
Lamont, Elizabeth B., James E. Herndon, Jane C. Weeks, I Craig Henderson, Rogerio Lilenbaum, Richard L. Schilsky, and Nicholas A. Christakis. “Criterion validity of Medicare chemotherapy claims in Cancer and Leukemia Group B breast and lung cancer trial participants.J Natl Cancer Inst 97, no. 14 (July 20, 2005): 1080–83. https://doi.org/10.1093/jnci/dji189.
Lamont EB, Herndon JE, Weeks JC, Henderson IC, Lilenbaum R, Schilsky RL, et al. Criterion validity of Medicare chemotherapy claims in Cancer and Leukemia Group B breast and lung cancer trial participants. J Natl Cancer Inst. 2005 Jul 20;97(14):1080–3.
Lamont, Elizabeth B., et al. “Criterion validity of Medicare chemotherapy claims in Cancer and Leukemia Group B breast and lung cancer trial participants.J Natl Cancer Inst, vol. 97, no. 14, July 2005, pp. 1080–83. Pubmed, doi:10.1093/jnci/dji189.
Lamont EB, Herndon JE, Weeks JC, Henderson IC, Lilenbaum R, Schilsky RL, Christakis NA. Criterion validity of Medicare chemotherapy claims in Cancer and Leukemia Group B breast and lung cancer trial participants. J Natl Cancer Inst. 2005 Jul 20;97(14):1080–1083.
Journal cover image

Published In

J Natl Cancer Inst

DOI

EISSN

1460-2105

Publication Date

July 20, 2005

Volume

97

Issue

14

Start / End Page

1080 / 1083

Location

United States

Related Subject Headings

  • United States
  • Retrospective Studies
  • Reproducibility of Results
  • Randomized Controlled Trials as Topic
  • Paclitaxel
  • Oncology & Carcinogenesis
  • Multicenter Studies as Topic
  • Medicare
  • Male
  • Lung Neoplasms